XM does not provide services to residents of the United States of America.
I
I

Incyte


News

U.S. BlackRock, Goldman Sachs, Netflix

U.S. RESEARCH ROUNDUP-BlackRock, Goldman Sachs, Netflix July 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including BlackRock, Goldman Sachs and Netflix, on Tuesday. HIGHLIGHTS * Ameriprise Financial Inc AMP.N : RBC raises target price to $487 from $480 * BlackRock BLK.N : JP Morgan raises target price to $774 from $756 * Goldman Sachs GS.N : HSBC raises target price to $527 from $493 * Moody's Corp MCO.N : JP Morgan rai
B
G
I
N
G
S
W
A
P

U.S. STOCKS Helios Technologies, Indivior, Principal Financial

BUZZ-U.S. STOCKS ON THE MOVE-Helios Technologies, Indivior, Principal Financial Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq hovered at record highs on Tuesday, propelled by gains in Nvidia and other megacaps, as U.S.
I
I
N
P
T
C
U
U
S

U.S. STOCKS Tesla, Archer Aviation, Novo Nordisk

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Archer Aviation, Novo Nordisk Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 edged up on Tuesday, boosted by gains in Tesla and megacap stocks, while the Dow was flat with investors assessing Federal Reserve Chairman Jerome Powell's comments on the need for more evidence before cutting rates.
I
P
P
P
P
T
L
O
W
U
U
U

U.S. STOCKS Tesla, Pure Storage, Rivian

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Pure Storage, Rivian Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street indexes traded lower on Tuesday after Federal Reserve Chairman Jerome Powell said more evidence was needed before cutting interest rates, while gains in Tesla shares kept losses in check.
I
P
P
T
L
O
W
U
U
U

U.S. STOCKS PayPal, Paramount Global, Novo Nordisk

BUZZ-U.S. STOCKS ON THE MOVE-PayPal, Paramount Global, Novo Nordisk Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street was on track for a lower open on Tuesday as megacap stocks retreated after a strong session, with additional caution creeping in ahead of jobs opening data and comments from Federal Reserve Chairman Jerome Powell later in the day.
I
P
T
U
R

U.S. STOCKS Atlassian, Comerica, Tesla

BUZZ-U.S. STOCKS ON THE MOVE-Atlassian, Comerica, Tesla Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures fell on Tuesday as megacap stocks retreated after a strong session, with additional caution creeping in ahead of jobs opening data and comments from Federal Reserve Chairman Jerome Powell later in the day.
I
T
U
R

Incyte drops after BMO downgrades to 'underperform'

BUZZ-Incyte drops after BMO downgrades to 'underperform' ** Shares of drugmaker Incyte Corp INCY.O down ~3% at $59.01 in premarket trading ** BMO Capital Markets cuts stock to "underperform" from "market perform"; trims PT to $48 from $52 ** Says co's $2 bln Dutch auction has cut capacity to acquire while generating minimal incremental value for sh
I

U.S. Deckers Brands, Nvidia, Workday

U.S. RESEARCH ROUNDUP-Deckers Brands, Nvidia, Workday May 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Deckers Brands, Nvidia and Workday, on Friday. HIGHLIGHTS * Deckers Brands DECK.N : Barclays raises target price to $1089 from $1026 * Enersys ENS.N : BTIG cuts to neutral from buy * Nvidia Corp NVDA.O : Deutsche Bank raises target price to $1000 * Ulta Beauty Inc ULTA.O : Jefferies cuts target price to $412 fr
A
I
I
N
A
R
U

S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT S&P 500 .SPX Top Performers Percent Change Incyte Corp INCY.OQ +8.2% Moderna Inc MRNA.OQ +6.3% Walgreens Boots Alliance Inc WBA.OQ +5.6% American Airlines Group Inc AAL.OQ +4.1% Carmax Inc KMX.N +3.9% Bottom Performers Percent Change Mettler-Toledo International Inc MTD.N -4.0%
I
W
A
U
H
C
M

U.S. STOCKS Annexon, MKS Instruments, Robinhood

BUZZ-U.S. STOCKS ON THE MOVE-Annexon, MKS Instruments, Robinhood Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock indexes edged higher on Monday, nearing record highs after a recent run of gains, as investors awaited key inflation figures this week to gauge the likelihood of interest rate cuts in 2024. .N At 11:58 a.m.
A
C
G
G
I
N
U
U
H
C
M

S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT S&P 500 .SPX Top Performers Percent Change Incyte Corp INCY.OQ +7.4% Carmax Inc KMX.N +5.1% Walgreens Boots Alliance Inc WBA.OQ +4.6% Moderna Inc MRNA.OQ +4.5% American Airlines Group Inc AAL.OQ +4.3% Bottom Performers Percent Change Mettler-Toledo International Inc MTD.N -2.5%
I
W
A
U
H
U
C
M

Incyte jumps on $2 bln share buyback plan

BUZZ-Incyte jumps on $2 bln share buyback plan ** Shares of Incyte INCY.O jump 6.2% premarket to $56.35, over 1-mth high, as biopharma firm announces $2 bln stock buyback plan ** Co commences modified "Dutch Auction" tender offer to repurchase shares for aggregate purchase price of up to $1.672 bln ** In addition, co entered into stock purchase agreement with Baker Bros Advisors, top INCY holder (per LSEG), to repurchase up to $328 worth of shares to enable the investment manager to maintain its
I

Incyte Announces Intention To Buy Back Up To $2.0 Billion Of Its Common Stock

BRIEF-Incyte Announces Intention To Buy Back Up To $2.0 Billion Of Its Common Stock May 13 (Reuters) - Incyte Corp INCY.O : INCYTE ANNOUNCES INTENTION TO BUY BACK UP TO $2.0 BILLION OF ITS COMMON STOCK INCYTE CORP - INCYTE COMMENCES DUTCH AUCTION TENDER OFFER TO REPURCHASE UP TO $1.67 BILLION OF OUTSTANDING COMMON SHARES Source text for Eikon: ID:n
I

U.S. STOCKS Molson Coors, Starbucks, Warner Bros Discovery

BUZZ-U.S. STOCKS ON THE MOVE-Molson Coors, Starbucks, Warner Bros Discovery Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes fell on Tuesday with caution prevailing ahead of the Federal Reserve's interest-rate decision and as stronger-than-expected labor costs hinted at persistent inflation.
A
I
P
P
S
T
A
S
U
U
E
R
G
L
M
T

U.S. STOCKS Zebra Technologies, Ecolab, American Electric Power

BUZZ-U.S. STOCKS ON THE MOVE-Zebra Technologies, Ecolab, American Electric Power Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes fell on Tuesday with caution prevailing ahead of the Federal Reserve's interest-rate decision and as stronger-than-expected labor costs hinted at persistent inflation.
I
P
P
T
C
S
U
U
E
R
G
L
T

Incyte Corp reports results for the quarter ended in March - Earnings Summary

Incyte Corp reports results for the quarter ended in March - Earnings Summary Incyte Corp INCY.OQ reported quarterly adjusted earnings of 64 cents​​ per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of 37 cents. The mean expectation of twenty analysts for the quarter was for earnings of 84 cents per share.
I

Incyte misses quarterly profit on weak sales of lead drug

Incyte misses quarterly profit on weak sales of lead drug April 30 (Reuters) - Incyte Corp INCY.O on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%. The company is working on strengthening its pipeline to counter competition from newly approved drugs, which could impact sales of Jakafi, the company's biggest-selling drug, as it nears the loss of exclusivity later this decade.
I
M
N

U.S. STOCKS LendingTree, Leidos, Roku

BUZZ-U.S. STOCKS ON THE MOVE-LendingTree, Leidos, Roku Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Futures tracking Wall Street's main indexes were subdued on Tuesday as investors refrained from placing big bets ahead of the Federal Reserve's interest rate decision and kept a close eye on a stream of earnings updates.
I
P
T
C
S
U
R
L

Incyte Corp falls on lower-than-expected revenue, profit

BUZZ-Incyte Corp falls on lower-than-expected revenue, profit ** Shares of drugmaker Incyte Corp INCY.O fall 2.9% to $51 premarket ** Co reports 9% growth in Q1 revenue of $880.9 mln, but misses analysts' estimates of $923.6 -LSEG data ** Posts Q1 adj.profit of 64 cents per share, also missing estimates of 84 cents per share- LSEG data ** Revenue f
I

Incyte Q1 Adjusted EPS USD 0.64 Vs. IBES Estimate USD 0.84

BRIEF-Incyte Q1 Adjusted EPS USD 0.64 Vs. IBES Estimate USD 0.84 Apr 30 (Reuters) - Incyte Q1 operating income USD 91.898 million. Q1 revenue USD 880.889 million vs. IBES estimate USD 923.6 million Q1 adjusted operating income USD 161.183 million vs. IBES estimate USD 206.3 million Q1 EPS USD 0.75
I



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.